Glen Clova Scientific (GCS) is developing a virus-like particle (VLP) technology platform that underpins a pipeline of biologic drug candidates for chronic inflammatory and autoimmune conditions. The company has three initial preclinical assets: GCS001 for senile pruritus, GCS002 for atopic dermatitis and GCS003 for eczema and asthma. GCS says its VLP platform can deliver enhanced performance and a simpler, more cost-effective manufacturing process compared with existing biologic drugs. The firm plans to advance preclinical development of these three assets and to exploit its platform in several non-pharmaceutical markets through partnerships. GCS was founded in 2022 as a spin-out from the University of Dundee. The recent financing provides capital to progress the pipeline and expand the proprietary technology platform.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2024